Subscribe
Conference Correspondent

Chemohormonal Therapy versus Hormonal Therapy Alone in Men with Metastatic Prostate Cancer

Conference Correspondent - ESMO 2014 - Prostate Cancer

Although the majority of patients with metastatic castrate-resistant prostate cancer (mCRPC) respond to androgen-deprivation therapy (ADT), prostate cancer will recur in many patients undergoing ADT. Because docetaxel has been shown to prolong overall survival (OS) in men with CRPC, Sweeney and colleagues reported on their trial that evaluated whether adding docetaxel to the treatment regimen improves OS when given at the time of starting ADT (Sweeney C, et al. ESMO 2014: Abstract 756O). 
A total of 790 men with CRPC were randomized in a 1:1 ratio to receive ADT alone or ADT plus docetaxel 75 mg/m2 every 3 weeks for 6 cycles within 4 months of initiating ADT. Patients were stratified based on high-volume versus low-volume disease, where high-volume disease included those with visceral metastases and/or ≥4 bone metastases, with at least 1 outside the vertebral column and pelvis.

The Table shows the results of ADT versus ADT plus docetaxel for the patients with high-volume disease. Decrease in prostate-specific antigen (PSA) to <0.2 ng/mL at 12 months, the time to PSA progression or to clinically progressive disease, and median OS were all significantly superior in the group receiving ADT plus docetaxel compared with the group receiving ADT alone. Grade 3 or 4 treatment-related adverse events were comparable in the 2 groups.

These data indicate that ADT plus docetaxel significantly improves disease control and OS compared with ADT alone in men with high-volume mCRPC.


Table

Related Items
Emerging Agents for Metastatic Prostate Cancer: Galeterone, Selinexor, and ARN-509
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Early PSA Response as a Prognostic Factor in Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Adding Docetaxel to ADT Significantly Improves Survival versus ADT Alone in Patients with High-Volume Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Androgen Receptor and CYP17A1 Copy Number Variations as Predictors of Outcomes in Patients with Metastatic Prostate Cancer Receiving Abiraterone
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Updated STRIDE and STAND Trial Results: Optimal Sipuleucel-T Use in Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
AR-V7 Splice Variant as Prognostic Marker for Resistance to Enzalutamide or Abiraterone in Men with Metastatic Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Maximal Androgen Depletion with Abiraterone Acetate Followed by Molecular-Targeted Therapies in Metastatic Prostate Cancer: Finding an Androgen-Signaling Signature to Predict Response
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Enzalutamide Long-Term Safety and Efficacy in Hormone-Naïve Prostate Cancer
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Sequencing Abiraterone Acetate, Cabazitaxel, and Enzalutamide in Post-Docetaxel mCRPC: Exploiting Efficacy and Avoiding Cross-Resistance
Conference Correspondent published on September 30, 2014 in ESMO 2014 - Prostate Cancer
Prognostic Factors for Sequencing Abiraterone, Cabazitaxel, and Enzalutamide in the Post-Docetaxel Setting
Conference Correspondent published on September 28, 2014 in ESMO 2014 - Prostate Cancer
Last modified: July 9, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology